113 related articles for article (PubMed ID: 17635371)
41. [Treatment of chronic hepatitis C with peginterferon alpha-2a and the factors influencing the effect of this treatment].
Jin GD; Gong QM; Mao HJ; Xu DZ; Lu ZM
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):302-4. PubMed ID: 15850524
[No Abstract] [Full Text] [Related]
42. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.
van der Eijk AA; Vrolijk JM; Haagmans BL
N Engl J Med; 2006 Mar; 354(12):1323-4. PubMed ID: 16554542
[No Abstract] [Full Text] [Related]
43. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.
Daud AI; Xu C; Hwu WJ; Urbas P; Andrews S; Papadopoulos NE; Floren LC; Yver A; Deconti RC; Sondak VK
Cancer Chemother Pharmacol; 2011 Mar; 67(3):657-66. PubMed ID: 20509027
[TBL] [Abstract][Full Text] [Related]
44. HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life.
Bae S; Sim T; Lim C; Kim D; Lee J; Park Y; Jung S; Choi I; Kwon S; Oh KT
Int J Pharm; 2017 Dec; 534(1-2):89-96. PubMed ID: 28982547
[TBL] [Abstract][Full Text] [Related]
45. [Changes of the serum adiponectin during treatment with peginterferon α-2a and ribavirin for chronic hepatitis C].
Huang P; Yang YF; Xiong QF; Zhong YD
Zhonghua Gan Zang Bing Za Zhi; 2012 May; 20(5):394-5. PubMed ID: 22988588
[No Abstract] [Full Text] [Related]
46. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
47. [Pegylated interferons: pharmacological basis].
Macquin-Mavier I; Hezode C; Dhumeaux D
Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
[No Abstract] [Full Text] [Related]
48. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
[TBL] [Abstract][Full Text] [Related]
49. Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B.
Bi J; Li X; Liu J; Chen D; Li S; Hou J; Zhou Y; Zhu S; Zhao Z; Qin E; Wei Z
Sci Rep; 2017 Aug; 7(1):7893. PubMed ID: 28801680
[TBL] [Abstract][Full Text] [Related]
50. Peginterferon α-2a for the treatment of HIV infection.
Asmuth DM; Utay NS; Pollard RB
Expert Opin Investig Drugs; 2016; 25(2):249-57. PubMed ID: 26667398
[TBL] [Abstract][Full Text] [Related]
51. [The interferons: pharmacology, mechanism of action, tolerance and side effects].
Arnaud P
Rev Med Interne; 2002 Nov; 23 Suppl 4():449s-458s. PubMed ID: 12481400
[TBL] [Abstract][Full Text] [Related]
52. [Pegylated interferons: preliminary review of their pharmacokinetic characteristics].
Azanza Perea JR
Rev Clin Esp; 2001 Apr; 201(4):205-12. PubMed ID: 11447908
[No Abstract] [Full Text] [Related]
53. [Neck pain and fever after peginterferon alpha-2a].
Moser C; Furrer J; Ruggieri F
Praxis (Bern 1994); 2007 Feb; 96(6):205-7. PubMed ID: 17330412
[TBL] [Abstract][Full Text] [Related]
54. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease.
Davidsen B; Munkholm P; Schlichting P; Nielsen OH; Krarup H; Bonnevie-Nielsen V
Aliment Pharmacol Ther; 1995 Feb; 9(1):75-9. PubMed ID: 7766748
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Hu X; Seddighzadeh A; Stecher S; Zhu Y; Goyal J; Matson M; Marbury T; Smith W; Nestorov I; Hung S
J Clin Pharmacol; 2015 Feb; 55(2):179-88. PubMed ID: 25187030
[TBL] [Abstract][Full Text] [Related]
56. Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers.
Foser S; Weyer K; Huber W; Certa U
Pharmacogenomics J; 2003; 3(6):312-9. PubMed ID: 14569259
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
Mager DE; Neuteboom B; Jusko WJ
Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230
[TBL] [Abstract][Full Text] [Related]
58. Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.
Patel TB; Pequignot E; Parker SH; Leavitt MC; Greenberg HE; Kraft WK
Int J Clin Pharmacol Ther; 2007 Mar; 45(3):161-8. PubMed ID: 17416111
[TBL] [Abstract][Full Text] [Related]
59. Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.
Jeon S; Juhn JH; Han S; Lee J; Hong T; Paek J; Yim DS
J Transl Med; 2013 Oct; 11():240. PubMed ID: 24088361
[TBL] [Abstract][Full Text] [Related]
60. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Munafo A; Trinchard-Lugan I; Nguyen TX; Buraglio M
Eur J Neurol; 1998 Mar; 5(2):187-193. PubMed ID: 10210831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
